'Ongoing progress' in Guernsey's mental health strategy report
'Clear and accessible'
The States said the strategy was made up of four pillars of work, including collating bailiwick datasets, early intervention, service improvements, and responding to recommendations of external reviews.It said: "Work has begun to develop a directory of mental health and wellbeing services, as well as map an island-wide network of care pathways. "Once complete, the resources will provide clear and accessible information so residents can better understand how to navigate local mental health and wellbeing services, and understand the support that is available to them. "Alongside this project, work remains ongoing to develop information and guidance for people to safely access formally accredited private therapy on-island."The report showed the overall mental health strategy to be 42% complete, with 78% of actions started and 11% of actions completed.Mr Leadbetter said: "I am very pleased with the publication of the first full annual report on the Mental Health and Wellbeing Strategy, which highlights our progress made since its launch in September 2023. "I would like to thank all members of the technical team and supporting officers for their dedication and hard work in helping design and implement the strategy."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
7 hours ago
- Reuters
US FDA approves Ionis' drug for rare genetic disorder
Aug 21 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' (IONS.O), opens new tab drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder. The drug, Dawnzera, is approved to prevent symptoms of a rare genetic disease called hereditary angioedema (HAE) in adults and pediatric patients over 12 years old. The condition causes frequent attacks of severe swelling in various parts of the body, including the hands, feet, genitals and face. Dawnzera will be available in the U.S. in the coming days, the company said. HAE is estimated to affect about 7,000 patients in the U.S., according to Ionis.
Reuters
a day ago
- Reuters
Rocket Pharma's shares soar after US FDA lets gene therapy trial resume
Aug 20 (Reuters) - The U.S. health regulator has allowed a study of Rocket Pharmaceuticals' (RCKT.O), opens new tab gene therapy to resume, less than three months after halting it following a patient's death. The drugmaker's shares soared over 30% in morning trading on Wednesday. Rocket's mid-stage trial, testing its experimental therapy, RP-A501, for a genetic disorder called Danon disease, was halted in May by the Food and Drug Administration after a patient died from a rare complication. The company said on Wednesday that the FDA has lifted its clinical hold on the trial, to be resumed with a revised pre-treatment regime and a lower dose of the gene therapy. Rocket said it will discontinue prophylactic use of drugs that inhibit the C3 protein, which is part of the immune system, as part of the pre-treatment regime. The patient who died in the May trial was one of two who were administered the C3 inhibitors. The patient had suffered from capillary leak syndrome, which can cause organ failure. In the new trial, three patients, at least four weeks apart, are expected to receive a lower dose of its therapy. Rocket said the adjusted dose was proposed based on data from an early-stage study, which showed a better safety profile. Danon disease, which affects males more severely than females, causes heart muscle damage and progressive muscle weakness. Fewer than 1,000 people in the United States are currently known to have the condition, according to National Institutes of Health.
BBC News
2 days ago
- BBC News
Walmart recalls shrimp after FDA warns of radioactive isotopes
Walmart has recalled some shrimp products in 13 US states after one shipment of seafood tested positive for radioactive contamination. The US Food and Drug Administration said varieties of frozen shrimp sold under Walmart's Great Value label could have been exposed to a dangerous isotope in shipping containers. One sample of breaded shrimp tested positive for the substance, but this positive sample "did not enter US commerce", the FDA said. Consumers are advised to throw away recently bought Walmart shrimp that matches this description - and not to eat or serve it. "The health and safety of our customers is always a top priority," a Walmart spokesperson told the BBC. "We have issued a sales restriction and removed this product from our impacted stores. We are working with the supplier to investigate."The spokesperson added that consumers who bought the recalled products can visit any Walmart location for a full refund. The recalled shrimp was sold at Walmart locations in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, and shoppers in those states were advised to be cautious. It came from an Indonesian supplier that has since had multiple shipping containers denied entry to the US, the FDA said. One shipment tested positive for Cesium-137, the radioactive form of the chemical element Cesium. The amount contained in the tested shipment held by the FDA was not enough to pose acute harm to consumers, but exposure over time could pose an elevated risk of cancer by damaging living cells in the body, said FDA officials.
